dc.contributor.author
Novohradsky, Vojtech
dc.contributor.author
Zamora, Ana
dc.contributor.author
Gandioso, Albert
dc.contributor.author
Brabec, Viktor
dc.contributor.author
Ruiz, José
dc.contributor.author
Marchán Sancho, Vicente
dc.date.issued
2017-07-10T10:15:57Z
dc.date.issued
2017-07-10T10:15:57Z
dc.date.issued
2017-04-25
dc.date.issued
2017-07-10T10:15:57Z
dc.identifier
https://hdl.handle.net/2445/113562
dc.description.abstract
A novel somatostatin receptor-targeted anticancer agent based on the conjugation of a highly cytotoxic and luminiscent cyclometalated iridium(III) complex to tumor-targeting vectors based on octreotide peptide has been described, and its potential for targeted theranostic applications has been demonstrated.
dc.format
application/pdf
dc.format
application/pdf
dc.publisher
Royal Society of Chemistry
dc.relation
Reproducció del document publicat a: https://doi.org/10.1039/c7cc01946g
dc.relation
Chemical Communications, 2017, vol. 53, p. 5523-5526
dc.relation
https://doi.org/10.1039/c7cc01946g
dc.rights
cc-by (c) Novohradsky, Vojtech et al., 2017
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Química Inorgànica i Orgànica)
dc.title
Somatostatin receptor-targeted organometallic iridium(III) complexes as novel theranostic agents
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
